RadNet, Inc. (RDNT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
$70.87-1.53%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
RadNet grows revenue 22% yearly by buying strategic businesses like Gleamer SAS. Cash from operations is improving, reaching $79 million in Q1 2026. The company raised free cash flow guidance to $122 million for 2026. These show progress in fixing the business and growing.
RadNet is still loss-making with operating income down to -$23.9 million in Q1 2026. Moody's downgraded its debt, signaling financial strain. The company faces pressure from high debt and cost challenges, risking further earnings weakness.
The market expects about 18% revenue growth next year, which is slightly below RadNet's recent 22% growth. The stock trades above consensus price targets, reflecting optimism on turnaround progress but also risk from losses and debt.
Breaks if: cash from operations falls below $70 million next year
Focus on improving cash from operating activities and free cash flow to support growth and financial flexibility.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a growth opportunity in the healthcare sector, particularly focused on expanding revenue through acquisitions and digital health. The current thesis state is intact, supported by strong recent financial performance.
The market appears to price in a divergence where RDNT is seen as relatively cheap compared to peers, but with expectations that may not fully reflect its recent growth. The valuation is considered unjustified given the company's loss-making status.
Fundamentals are likely to show continued strong revenue growth, driven by strategic acquisitions and digital health expansion. However, cash flow improvement is mixed, and there is a moderate risk of earnings surprises trending down.
The long-term thesis hinges on management's ability to maintain guidance and execute on their priorities, especially in a potentially weakening economic environment. Additionally, the performance of sector bellwethers could influence RDNT's momentum.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. Analysts expect revenue growth to accelerate to 22.1% year-on-year. This is an improvement from the 8.4% increase in the same quarter last year. However, profit growth is lagging, which may hinder revenue expansion efforts.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Free Cash Flow guidance for the Imaging Center segment was revised upwards from $105 - $115 million to $115 - $125 million in 2026. Cash from operating activities was $78.97 million in 2026-Q1 and $84.16 million in 2025-Q4, showing stable cash generation. The trajectory is delivering with improved guidance reflecting operational cash flow strength.
“RadNet revises upwards 2026 Imaging Center guidance levels with increases to Free Cash Flow.”
“RadNet revises full-year 2026 Imaging Center guidance levels with increases to Free Cash Flow.”
“RadNet increased guidance ranges for Revenue and Adjusted EBITDA, supporting cash flow growth.”
Breaks if: free cash flow falls below $112 million in 2026
Focus on improving cash from operating activities and free cash flow to support growth and financial flexibility.
Management stated this priority in 3 quarters including 2025-Q4, 2026-Q1, and 2026-Q2. Free Cash Flow guidance for the Imaging Center segment was revised upwards from $105 - $115 million to $115 - $125 million in 2026. Cash from operating activities was $78.97 million in 2026-Q1 and $84.16 million in 2025-Q4, showing stable cash generation. The trajectory is delivering with improved guidance reflecting operational cash flow strength.
“RadNet revises upwards 2026 Imaging Center guidance levels with increases to Free Cash Flow.”
“RadNet revises full-year 2026 Imaging Center guidance levels with increases to Free Cash Flow.”
“RadNet increased guidance ranges for Revenue and Adjusted EBITDA, supporting cash flow growth.”
Breaks if: operating income remains negative or worsens over next year
Aim to enhance operating income through cost management and revenue growth.
Breaks if: YoY revenue growth falls below ~18% next year
Continue growth by acquiring companies like Gleamer to enhance Digital Health segment and overall revenue.
Stated as a priority in 3 quarters including 2026-Q1, Q2, and 2025-Q4. Total Company Revenue grew 25.0% from $498.2 million in 2025-Q2 to $622.7 million in 2026-Q2. Digital Health Annual Recurring Revenue nearly doubled from $53.5 million in 2025-Q2 to $105.5 million in 2026-Q2, with management expecting ARR to approach or exceed $140 million by end of 2026. The trajectory is delivering with strong growth driven by the Gleamer acquisition and Digital Health expansion.
“RadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA and Free Cash Flow.”
“The Digital Health division continues to gain momentum, advanced by the March 2, 2026 acquisition of Gleamer SAS in France.”
“RadNet announced acquisition of Gleamer SAS to expand DeepHealth's AI-powered health informatics solutions.”
Over the next 1 to 3 years, RDNT's trajectory will depend on its operational execution and external economic factors. Not investment advice.